Form 4: SoftBank Affiliates Sell Vir Bio Shares

Affiliates of SoftBank Vision Fund sold over 460,000 shares of Vir Biotechnology common stock in late November 2025, reducing their beneficial ownership.

Summary

• SVF Endurance (Cayman) Ltd, SoftBank Vision Fund (AIV M1) L.P., and SB Investment Advisers (UK) Ltd, all related entities, reported sales of Vir Biotechnology, Inc. (VIR) common stock.
• The reporting persons are identified as a 10% owner and have director representation on the issuer's board.
• On November 24, 2025, 227,803 shares of common stock were sold at a weighted average price of $6.1491 per share, with prices ranging from $5.93 to $6.30.
• On November 25, 2025, an additional 235,971 shares of common stock were sold at a weighted average price of $6.38 per share, with prices ranging from $6.12 to $6.6094.
• These sales were executed pursuant to a Rule 10b5-1 trading plan established by the Reporting Person on September 3, 2025.
• Following these transactions, the beneficial ownership of the reporting persons in Vir Biotechnology, Inc. stands at 14,110,209 shares of common stock.
• SVF Endurance (Cayman) Limited is the record holder of the shares and is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P., with SB Investment Advisers (UK) Limited managing the fund.

Sentiment

Score: 3

Explanation: The significant insider selling by a major institutional investor and 10% owner, SoftBank Vision Fund affiliates, typically signals a lack of confidence or a strategic portfolio rebalancing, which can be perceived negatively by the market.

Negatives

• Significant insider selling by a major institutional investor (SoftBank affiliates) and 10% owner, which can be interpreted as a reduction in confidence or a strategic divestment.
• The reduction in beneficial ownership by a key institutional stakeholder could lead to negative market sentiment.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Sales of common stock by SVF Endurance (Cayman) Ltd, a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P., which is a 10% owner and has director representation on Vir Biotechnology's board, constitute related party transactions.

Stakeholder Impact

• Shareholders: The sale by a significant institutional investor and director could lead to negative market sentiment and potentially impact the share price.
• Other stakeholders (employees, customers, suppliers, creditors): No direct impact is explicitly mentioned or implied by this specific transaction report.

Key Dates

Recommendation

The significant sale of shares by a major institutional investor and 10% owner, SoftBank Vision Fund affiliates, suggests a potential reduction in conviction or a strategic portfolio rebalancing. While not a full divestment, such insider selling can create negative sentiment and warrants a cautious 'hold' stance for existing investors, prompting further investigation into the company's fundamentals and future prospects. New investors should exercise caution.

Keywords

Vir Biotechnology, VIR, SoftBank Vision Fund, SVF Endurance, Insider Sale, Form 4, Stock Transaction, Biotechnology, Institutional Investor, 10b5-1 Plan